Twice each month the CEA Registry Blog lists recently published cost utility studies and associated papers. 16 papers were listed this time. Here's a handful:
Soini EJ, Martikainen JA, Nousiainen T. Treatment of follicular non-Hodgkin's lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up. Ann Oncol. 2010 Dec 6. [Epub ahead of print]
Mavranezouli I. A review and critique of studies reporting utility values for schizophrenia-related health states. Pharmacoeconomics. 2010 Dec 1;28(12):1109-21.
Jit M, Cromer D, Baguelin M, et al. The cost-effectiveness of vaccinating pregnant women against seasonal influenza in England and Wales. Vaccine. 2010 Dec 10;29(1):115-22.
Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis. 2010 Dec;10(12):845-52.
Clement FM, Klarenbach S, Tonelli M, et al. An economic evaluation of erythropoiesis-stimulating agents in CKD. Am J Kidney Dis. 2010 Dec;56(6):1050-61.
Gohel MS, Epstein DM, Davies AH. Cost-effectiveness of traditional and endovenous treatments for varicose veins. Br J Surg. 2010 Dec;97(12):1815-23.